Pioneers: Phase Iii Trials of A Novel Immunotherapy To Evaluate Efficacy In A Range of Tumor Types Trademark Details

This mark is dead with a status of Abandoned-Failure to Respond or Late Response. The last case file activity for this mark occured 14 years ago on Wednesday, March 17, 2010, according to the United State Patent & Trademark Office
Word Mark Pioneers: Phase III Trials of a Novel Immunotherapy to Evaluate Efficacy in a Range of Tumor Types
Status Dead 602 — Abandoned-Failure to Respond or Late Response

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 77741348
Status Date Wednesday, March 17, 2010
Filing Date Wednesday, March 17, 2010
Attorney Nadine P. Flynn

Correspondent

NADINE P. FLYNN
BRISTOL-MYERS SQUIBB COMPANY
345 PARK AVENUE
NEW YORK, NY 10154

Case File Statements

Goods & Services Medical and scientific research, namely, conducting clinical trials relating to pharmaceutical preparations for human use
Pseudo Mark Pioneers: Phase Three Trials of a Novel Immunotherapy to Evaluate Efficacy in a Range of Tumor Types

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 6 — Active
Status Date Tuesday, May 26, 2009
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.